Biagio Ricciuti, Thoracic Medical Oncologist at Dana-Farber Cancer Institute, shared on LinkedIn:
“Thoughtful discussion today at Hawaii Lung26 with a stellar faculty on the evolving landscape of KRAS- and RAS-targeted therapies.
With Haniel Araujo M.D., Ravi Salgia, JHeymach, Joshua Sabari, Erminia Massarelli, MD, PhD, MS, Matthew Lee and Jonathan Riess.
Resistance to KRAS inhibitors is highly heterogeneous, driven by on-target alterations, adaptive reactivation, bypass signaling, and histologic transformation. Rational combinations, next-generation KRAS inhibitors, and broader RAS-targeted strategies offer promising paths forward.”
Other articles featuring Biagio Ricciuti and Lung cancer on OncoDaily.